Drug Type Bispecific antibody |
Synonyms AntiIL13 and TSLP (Sanofi), AntiIL13/TSLP (Sanofi) + [2] |
Target |
Mechanism IL-13 inhibitors(Interleukin-13 inhibitors), TSLP inhibitors(Thymic stromal lymphopoietin inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Start Date30 Sep 2024 |
Sponsor / Collaborator |
Start Date17 Jul 2024 |
Sponsor / Collaborator |
Start Date29 May 2024 |
Sponsor / Collaborator |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Asthma | Phase 2 | US | 16 Oct 2023 | |
Asthma | Phase 2 | MX | 16 Oct 2023 | |
Asthma | Phase 2 | KR | 16 Oct 2023 | |
Asthma | Phase 2 | GB | 16 Oct 2023 | |
Asthma | Phase 2 | JP | 16 Oct 2023 | |
Asthma | Phase 2 | CL | 16 Oct 2023 | |
Asthma | Phase 2 | IL | 16 Oct 2023 | |
Asthma | Phase 2 | CA | 16 Oct 2023 | |
Asthma | Phase 2 | IN | 16 Oct 2023 | |
Asthma | Phase 2 | CN | 16 Oct 2023 |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
No Data |